$0.00
(Market cap
$2 Mln
Recently Viewed
Clear AllMarket cap
$2 Mln
Revenue (TTM)
$120 Mln
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-69 Mln
ROE
-19.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.2
Debt to Equity
-6.5
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
8,703,100
CFO
$-730.45 Mln
EBITDA
$-792.43 Mln
Net Profit
$-971.90 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Athenex (ATNX)
| -99.8 | -96.2 | -99.5 | -100.0 | -97.0 | -89.1 | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|
|
Athenex (ATNX)
| -89.1 | -87.7 | -27.6 | 20.3 | -20.1 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery... product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. Read more
Chairman & CEO
Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.
Chairman & CEO
Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.
Headquarters
Buffalo, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Athenex Inc (ATNX) is $0.01 (NASDAQ) as of 26-Jul-2023 09:30 EDT. Athenex Inc (ATNX) has given a return of -97% in the last 3 years.
Since, TTM earnings of Athenex Inc (ATNX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Athenex Inc (ATNX) are Rs -- and Rs -- as of 24-Apr-2026.
Athenex Inc (ATNX) has a market capitalisation of $ 2 Mln as on 26-Jul-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Athenex Inc (ATNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.